Back to results
US 12,600,777 B2Granted
Combination therapies comprising antibody molecules to LAG-3
AssigneesNovartis AG, Immutep S.A.S.
InventorsGlenn Dranoff, Frederic Triebel, Chrystelle Brignone, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Ann Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
Life of this patent
Estimating the term…
Abstract
Combination therapies comprising antibody molecules that specifically bind to LAG-3 are disclosed. The combination therapies can be used to treat, prevent and/or diagnose cancerous or infectious disorders.
Claims7
A method of treating a cancer in a subject, comprising administering to the subject an anti-LAG-3 antibody molecule and an agent that enhances tumor antigen presentation
- thereby treating the cancer,
- wherein the anti-LAG-3 antibody molecule, comprises:
- (a) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO:
- 4, a VHCDR2 amino acid sequence of SEQ ID NO:
- 5, and a VHCDR3 amino acid sequence of SEQ ID NO:
- 3;
- and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO:
- 13, a VLCDR2 amino acid sequence of SEQ ID NO:
- 14, and a VLCDR3 amino acid sequence of SEQ ID NO:
- 15;
- (b) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO:
- 1;
- a VHCDR2 amino acid sequence of SEQ ID NO:
- 2;
- and a VHCDR3 amino acid sequence of SEQ ID NO:
- 3;
- and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO:
- 10, a VLCDR2 amino acid sequence of SEQ ID NO:
- 11, and a VLCDR3 amino acid sequence of SEQ ID NO:
- 12;
- (c) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO:
- 286, a VHCDR2 amino acid sequence of SEQ ID NO:
- 5, and a VHCDR3 amino acid sequence of SEQ ID NO:
- 3;
- and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO:
- 13, a VLCDR2 amino acid sequence of SEQ ID NO:
- 14, and a VLCDR3 amino acid sequence of SEQ ID NO:
- 15;
- or
- (d) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO:
- 286;
- a VHCDR2 amino acid sequence of SEQ ID NO:
- 2;
- and a VHCDR3 amino acid sequence of SEQ ID NO:
- 3;
- and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO:
- 10, a VLCDR2 amino acid sequence of SEQ ID NO:
- 11, and a VLCDR3 amino acid sequence of SEQ ID NO:
- 12, and
- wherein the agent that enhances tumor antigen presentation is a STING agonist, a TLR agonist, an A2AR antagonist, or an oncolytic virus, or a combination thereof.
37 more elements
Dependencies are inferred from the claim text.